Bin Lv

Prof. Bin Lv


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2025 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
HXHuizhen Xing
Huizhen Xing
XBXinwei Bai
Xinwei Bai
XPXiaoying Pei
Xiaoying Pei
YZYuqi Zhang
Yuqi Zhang
XZXueying Zhang
Xueying Zhang
XWXiaoli Wu
Xiaoli Wu
Oxidative stress and inflammatory dysregulation play crucial roles in pathogenesis of acute lung injury (ALI), and their cyclic synergy drives excessive inflammatory responses and further exacerbates ALI. Therefore, new effective strategies to treat ALI are urgently needed. Herein, a novel synergistic selenium based chlorogenic acid nanoparticle was developed to disrupt the cyclic synergistic effect between oxidative stress and inflammatory response in ALI. The chlorogenic acid, a polyphenol commonly found in herb, had been effectively conjugated with human serum albumin and coated on selenium nanoparticles (Se NPs) to create CHSe NPs. The CHSe NPs exhibited superoxide dismutase(SOD) like and glutathione peroxidase(GPX) like activities, effectively scavenging various types of reactive oxygen species (ROS), and inhibited the inflammatory response of macrophages. Additionally, with excellent biosafety, CHSe NPs exhibited superior therapeutic effects in ALI mice models in vivo, surpassing the performance of the clinic drug dexamethasone. They remarkably reduced ROS levels, and elevated the SOD and GPX enzyme activities in lung tissue to exert antioxidant effects. In addition, the CHSe NPs modulated the immune microenvironment of ALI by reversing M1 macrophage polarization, downregulating the expression levels of pro-inflammatory cytokines (IL-1β, IL-6, TNF-a), nitric oxide synthase (iNOS), and myeloperoxidase (MPO), and upregulating anti-inflammatory cytokine (IL-10) levels, thereby alleviating excessive inflammation and decreasing neutrophil infiltration. Further mechanistic research revealed that CHSe NPs directly acted on and modulated the expression of Mapk8ip1 and Itga2b, which were upstream proteins of MAPK signaling pathway and PI3K-Akt signaling pathway, therefore impeding the cyclic synergy between oxidative stress and inflammatory dysregulation. In summary, CHSe NPs synergistically exert antioxidant and anti-inflammatory effects by regulating the MAPK signaling pathway and PI3K-Akt signaling pathway, showing enormous potential in the treatment of ALI.

23 August 2024 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
JGJinhe Guo
Jinhe Guo
YZYuqi Zhang
Yuqi Zhang
YDYaodong Du
Yaodong Du
YCYang Chen
Yang Chen
XZXin Zhao
Xin Zhao
XGXiu-Mei Gao
Xiu-Mei Gao

2 September 2026 in International Journal of Molecular Medicine
Verified
Journal Article
Open access
PDF file
MZMinghui Zhang
Minghui Zhang
YZYuqi Zhang
Yuqi Zhang
HYHaoxin Yin
Haoxin Yin
JYJunyuan Yan
Junyuan Yan
YDYingling Dong
Yingling Dong
XGXiu-Mei Gao
Xiu-Mei Gao
Lysine acetylation is recognized as a critical and reversible post‑translational modification that is essential for numerous cellular functions and biological processes. The dynamic interplay between lysine acetylation and deacetylation to regulates a wide spectrum of processes, including histone modification, gene expression, cell cycle progression, DNA repair and signal transduction. Emerging evidence has demonstrated that the dysregulation of lysine acetylation is strongly associated with multiple diseases, including cancer, cardiovascular diseases, chronic inflammatory diseases and neurological diseases. These alterations can modify gene expression and disrupt cellular homeostasis. The present review aimed to highlight the biological functions of lysine acetyltransferases and lysine deacetylases, their contributions to disease pathogenesis, and the interplay the crosstalk of lysine acetylation with other post‑translational modifications. Drawing on the latest research findings, the therapeutic potential of targeting acetylation pathways is discussed, with the aim of providing new insight into the development of innovative treatment strategies and clinical applications.

14 February 2024 in Research Square
Verified
Preprint
Open access
PDF file
BLBin Lv
Bin Lv
XWXiaoying Wang
Xiaoying Wang
HYHaiyang Yu
Haiyang Yu
YCYang Chen
Yang Chen
JGJinhe Guo
Jinhe Guo
XGXiumei Gao
Xiumei Gao
Background: Hyperactive inflammation is crucial for the development of acute myocardial infarction (AMI) to heart failure and can promote impaired cardiac function, and it is difficult to determine its specific therapeutic targets and drugs. Therefore, it is necessary to develop new therapeutic strategies to control inflammatory responses to protect myocardial cells during AMI. Methods: Levels of critical cardiac markers and inflammatory factors were measured in blood samples collected from clinical patients with AMI to analyze the association between the serum expression levels of inflammatory factors and the progression of AMI. To uncover the mechanism underlying the association between inflammatory response and AMI, microarray analysis was performed to identify key myocardial cell regulators. ATAC-seq was also performed to identify how immune response genes are transcriptionally regulated by KAT2A. KAT2A-/- genetically engineered mice were used to validate the screened targets. Finally, a small molecule targeting KAT2A was developed and tested in a rat model of AMI. Results: Here we show that KAT2A, a histone H3K9 acetyltransferase, is a key factor regulating the inflammatory response in AMI. Specifically, the level of cardiac damage was initially found to be associated with the inflammatory response in patients with AMI. Regarding the mechanism, KAT2A transcriptionally regulates pro-inflammatory tumor necrosis factor alpha and interleukin-6 to induced cardiomyocyte damage. Using a genetically engineered mouse model of AMI, we show that targeted KAT2A loss or inhibition prevents the recruitment of immune cells into the myocardium to suppress the inflammatory explosion in AMI in vivo and significantly improved heart function. Finally, Tanshinone I, a KAT2A-targeted inhibitor, could inhibited the inflammatory response in AMI in vivo. Conclusion: KAT2A is a potential therapeutic target for AMI, especially for inhibiting the inflammatory response to this condition. As a specific KAT2A-targeted inhibitor, Tanshinone I is a potent candidate drug for AMI.